Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with High-Risk and Relapsed/Refractory Acute Myeloid Leukemia (AML)

Maro Ohanian, Tara L. Lin, Ellen Ritchie, Michael Craig, Apurv Agrawal, Kathleen G. Halka, Naveen Pemmaraju, Gautam Borthakur, Miranda Lim, Sherry A. Pierce, Ana Tari Ashizawa, Hagop Kantarjian, Jorge E. Cortes, Gail J. Roboz

Blood (2021) 138 (Supplement 1): 1281.

https://doi.org/10.1182/blood-2021-152750

Published: 2021

Journal Articles

Interim Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with Untreated Acute Myeloid Leukemia (AML)

Maro N. Ohanian, DO, Tara L Lin, MD, Ellen K. Ritchie, MD, Michael Craig, MD, Apurv Agrawal, MD, Kathleen G. Halka, MD, Vinit Karur, MD, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Sarah Aminov, Miranda Lim, BSN, Sherry A. Pierce, BSN, BA, Natalie Sacarakis, Stacy Minor, Ana Tari Ashizawa, PhD, William Hahne, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Gail J. Roboz, MD

Blood (2018) 132 (Supplement 1): 1387.

https://doi.org/10.1182/blood-2018-99-113693

Published: 2018

Journal Articles

An Open-Label, Phase I Study of Dasatinib in Combination with Decitabine in Patients (Pts) with Accelerated or Blastic Phase Chronic Myeloid Leukemia (CML)

Yasmin Abaza, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Naval Daver, MD, Farhad Ravandi, MD, Srdan Verstovsek, MD PhD, Jan A. Burger, MD PhD, Zeev Estrov, MD, Maro Ohanian, DO, Miranda Lim, BSN, Rita Assi, MD, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 5433.

https://doi.org/10.1182/blood.V128.22.5433.5433

Published: 2016

Journal Articles

Safety, Pharmacokinetics, and Efficacy of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)

Maro Ohanian, DO, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Michael Andreeff, MD PhD, Elias Jabbour, Marina Konopleva, MD PhD, Miranda Lim, BSN, Sherry Pierce, BSN, BA, Susan O'Brien, MD, Bradley G. Somer, MD, Ana Tari, PhD, William Wierda, MD PhD, Srdan Verstovsek, MD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 3801.

https://doi.org/10.1182/blood.V126.23.3801.3801

Published: 2015

Journal Articles

Frequency and Impact of Molecular Response’s with Nilotinib (Tasigna) in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP)

Naval Daver, Hagop M. Kantarjian, MD, Susan O'Brien, MD, Elias Jabbour, MD, Sherry Pierce, BSN, BA, Miranda Lim, BSN, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Marina Konopleva, MD PhD, Courtney D. DiNardo, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD

Blood (2014) 124 (21): 3156.

https://doi.org/10.1182/blood.V124.21.3156.3156

Published: 2014

NARROW

Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with High-Risk and Relapsed/Refractory Acute Myeloid Leukemia (AML)

Interim Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with Untreated Acute Myeloid Leukemia (AML)

An Open-Label, Phase I Study of Dasatinib in Combination with Decitabine in Patients (Pts) with Accelerated or Blastic Phase Chronic Myeloid Leukemia (CML)

Frequency and Impact of Molecular Response’s with Nilotinib (Tasigna) in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP)

Email alerts

ASH Publications

American Society of Hematology

Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with High-Risk and Relapsed/Refractory Acute Myeloid Leukemia (AML)

Interim Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with Untreated Acute Myeloid Leukemia (AML)

An Open-Label, Phase I Study of Dasatinib in Combination with Decitabine in Patients (Pts) with Accelerated or Blastic Phase Chronic Myeloid Leukemia (CML)

Frequency and Impact of Molecular Response’s with Nilotinib (Tasigna) in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only